$VRAY

United Therapeutics received a rating upgrade due to its promising drug Ralinepag, which is seen as a strong competitor to Yutrepia. Analysts believe that Ralinepag could significantly outperform market expectations, boosting United Therapeutics' stock value. The upgrade reflects increased confidence in the drug's efficacy and market potential. This news could attract more investors and positively impact the company's stock price in the near term. Overall, the sentiment surrounding United Therapeutics is markedly positive.